Recent advances in oral delivery of peptide hormones

References

• Nussey S, Whitehead S. Endocrinology: an integrated approach. Oxford: BIOS Scientific Publishers; 2001.
   Google Scholar
• Schally AV. Handbook of biologically active peptides. Miami (FL): Academic Press; 2006. p. Xliii–Xliii.
   Google Scholar
• Hall JE. Introduction to endocrinology. In: Gruliow R, editor. Guyton and hall textbook of medical physiology. Philadelphia (PA): William Schmitt Publishing; 2015. p. 925–937.
   Google Scholar
• Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004 Jan;57:6–14.
   PubMed Web of Science ®Google Scholar
• Renukuntla J, Vadlapudi AD, Patel A, et al. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013 Apr 15;447:75–93. DOI:10.1016/j.ijpharm.2013.02.030.
   PubMed Web of Science ®Google Scholar
• Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2013 Sep;18:807–817. DOI:10.1016/j.drudis.2013.05.011.
   PubMed Web of Science ®Google Scholar
• Uhlig T, Kyprianou T, Martinelli FG, et al. The emergence of peptides in the pharmaceutical business: from exploration to exploitation. EuPA Open Proteomics. 2014 9;4:58–69.
   Google Scholar
• Reichert J, Pechon P, Tartat A, et al. Development trends for peptide therapeutics: a comprehensive quantitative analysis of peptide therapeutics in clinical development. San Diego (CA): Peptide Therapeutics Foundation; 2010.
   Google Scholar
• Brayden DJ, O’Mahony DJ. Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. Pharm Sci Technol To. 1998 Oct;1:291–299. DOI:10.1016/S1461-5347(98)00075-3.
   Google Scholar
• Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003 Apr;2:289–295. DOI:10.1038/nrd1067.
   PubMed Web of Science ®Google Scholar
• Bastian SE, Walton PE, Ballard FJ, et al. Transport of IGF-I across epithelial cell monolayers. J Endocrinol. 1999 Sep;162:361–369. DOI:10.1677/joe.0.1620361.
   PubMed Web of Science ®Google Scholar
• Pawar VK, Meher JG, Singh Y, et al.Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J Control Release. 2014 Dec 28;196:168–183. DOI:10.1016/j.jconrel.2014.09.031.
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Leibach FH. Role of pH gradient and membrane-potential in dipeptide transport in intestinal and renal brush-border membrane-vesicles from the rabbit - studies with L-carnosine and glycyl-L-proline. J Biol Chem. 1983;258:4189–4192.
   Web of Science ®Google Scholar
• Langguth P, Bohner V, Heizmann J, et al. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release. 1997 May 5;46:39–57. DOI:10.1016/S0168-3659(96)01586-6.
   Web of Science ®Google Scholar
• Amritpal S, Ankush S, Pooja A. Novel approaches for colon targeted drug delivery system. Int J Res Dev Pharm Life Sci. 2014;3:877–886.
   Google Scholar
• Pauletti GM, Gangwar S, Knipp GT, et al. Structural requirements for intestinal absorption of peptide drugs. J Control Release. 1996;41:3–17. DOI:10.1016/0168-3659(96)01352-1.
   Web of Science ®Google Scholar
• Korjamo T, Heikkinen AT, Mönkkönen J. Analysis of unstirred water layer in in vitro permeability experiments. J Pharm Sci. 2009;98:4469–4479. DOI:10.1002/jps.21762.
   PubMed Web of Science ®Google Scholar
• Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliver Rev. 2006 Apr 20;58:15–28. DOI:10.1016/j.addr.2006.01.003.
   PubMed Web of Science ®Google Scholar
• Pauletti GM, Gangwar S, Siahaan TJ, et al. Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Adv Drug Deliver Rev. 1997 Sep 15;27:235–256. DOI:10.1016/S0169-409X(97)00045-8.
   PubMed Web of Science ®Google Scholar
• Ward PD, Tippin TK, Thakker DR. Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm Sci Technolo Today. 2000 Oct 1;3:346–358.
   PubMedGoogle Scholar
• Hamdan AM, Koyanagi S, Wada E, et al. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway. J Biol Chem. 2012 May 18;287:17224–17231. DOI:10.1074/jbc.M111.333377.
   PubMed Web of Science ®Google Scholar
• Moradi SV, Varamini P, Toth I. The transport and efflux of glycosylated luteinising hormone‐releasing hormone analogues in caco‐2 cell model: contributions of glucose transporters and efflux systems. J Pharm Sci. 2014;103:3217–3224. DOI:10.1002/jps.24120.
   PubMed Web of Science ®Google Scholar
• Patel A, Cholkar K, Mitra AK. Recent developments in protein and peptide parenteral delivery approaches. Ther Deliv. 2014 Mar;5:337–365. DOI:10.4155/tde.14.5.
   PubMedGoogle Scholar
• Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010 Jun;99:2557–2575. DOI:10.1002/jps.22054.
   PubMed Web of Science ®Google Scholar
• Magon N. Gonadotropin releasing hormone agonists: expanding vistas. Indian J Endocrinol Metab. 2011 Oct;15:261–267. DOI:10.4103/2230-8210.85575.
   PubMedGoogle Scholar
• Youn YS, Jung JY, Oh SH, et al. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release. 2006 Sep 12;114:334–342. DOI:10.1016/j.jconrel.2006.06.007.
   PubMed Web of Science ®Google Scholar
• Varasteh Moradi S, Varamini P, Steyn F, et al. In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. Int J Pharm. 2015 Aug 29;495:106–111. DOI:10.1016/j.ijpharm.2015.08.095.
   PubMed Web of Science ®Google Scholar
• Kipnes M, Dandona P, Tripathy D, et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care. 2003;26:421–426.
   PubMed Web of Science ®Google Scholar
• Rink R, Arkema-Meter A, BauDOIn I, et al. To protect peptide pharmaceuticals against peptidases. J Pharmacol Toxicol. 2010 Mar-Apr;61:210–218.
   PubMed Web of Science ®Google Scholar
• Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013 Aug;9:451–466. DOI:10.1038/nrendo.2013.120.
   PubMed Web of Science ®Google Scholar
• Van de Walle J, Van Herzeele C, Raes A. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf. 2010;33:261–271. DOI:10.2165/11319110-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Susaki H, Okuno S, et al. Renal drug targeting using a vector “alkylglycoside”. J Pharmacol Exp Ther. 1999 Jan;288:57–64.
   PubMed Web of Science ®Google Scholar
• Chikhale EG, Ng KY, Burton PS, et al. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res. 1994;11:412–419.
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Mrsny RJ. Oral peptide delivery: prioritizing the leading technologies. Ther Deliv. 2011 Dec;2:1567–1573.
   PubMedGoogle Scholar
• Antunes F, Andrade F, Ferreira D, et al. Models to predict intestinal absorption of therapeutic peptides and proteins. Curr Drug Metab. 2013;14:4–20.
   PubMed Web of Science ®Google Scholar
• Whitehead K, Karr N, Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm Res-Dordr. 2008 Aug;25:1782–1788. DOI:10.1007/s11095-007-9488-9.
   PubMed Web of Science ®Google Scholar
• Tozaki H, Emi Y, Horisaka E, et al. Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon. J Pharm Pharmacol. 1997;49:164–168.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Khan MA. Current status of the oral delivery of insulin. Pharm Technol. 2001;25:76–90.
   Google Scholar
• Ramesan RM, Sharma CP, Recent advances in the oral delivery of insulin. Recent Pat Drug Deliv Formul. 2014;8:155–159.
   PubMedGoogle Scholar
• Herrero EP, Alonso MJ, Csaba N. Polymer-based oral peptide nanomedicines. Ther Deliv. 2012 May;3:657–668.
   PubMedGoogle Scholar
• Chalasani KB, Russell-Jones GJ, Yandrapu SK, et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release. 2007 Feb 26;117:421–429. DOI:10.1016/j.jconrel.2006.12.003.
   PubMed Web of Science ®Google Scholar
• Li JQ, Wang YJ, Han LN, et al. Time-action profile of an oral enteric insulin formulation in healthy chinese volunteers. Clin Ther. 2012 Dec;34:2333–2338.
   PubMed Web of Science ®Google Scholar
• Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J. 2010 Apr;25:70–78. DOI:10.5001/omj.2010.24.
   Google Scholar
• Del Curto MD, Maroni A, Palugan L, et al. Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds. J Pharm Sci. 2011 Aug;100:3251–3259.
   PubMed Web of Science ®Google Scholar
• Katsuma M, Watanabe S, Takemura S, et al. Scintigraphic evaluation of a novel colon-targeted delivery system (CODES (TM)) in healthy volunteers. J Pharm Sci. 2004 May;93:1287–1299.
   PubMed Web of Science ®Google Scholar
• Urayama A, Yamada S, Kimura R, et al. Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL/6J mice. Life Sci. 2002 Dec 20;72:601–607.
   PubMed Web of Science ®Google Scholar
• Rajput SK, Krishnamoorthy S, Pawar C, et al. Antiepileptic potential and behavioral profile of L-pGlu-(2-propyl)-L-His-L-ProNH2, a newer thyrotropin-releasing hormone analog. Epilepsy Behav. 2009 Jan;14:48–53.
   PubMed Web of Science ®Google Scholar
• Khomane K, Kumar L, Meena CL, et al. NP-647, a novel TRH analogue: investigating physicochemical parameters critical for its oral and parenteral delivery. Int J Pharm. 2011 Mar 15;406:21–30. DOI:10.1016/j.ijpharm.2010.12.025.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Yamamura M, Sugihara J, et al. Taltirelin hydrate (TA-0910): an orally active thyrotropin-releasing hormone mimetic agent with multiple actions. CNS Drug Reviews. 1998;4:25–41. DOI:10.1111/j.1527-3458.1998.tb00039.x.
   Google Scholar
• Sugimoto M, Kitaoka K, Saito Y, et al. Orally rapidly disintegrating tablet, and process for producing same. Google Patents. 2012.
   Google Scholar
• Sasaki I, Tozaki H, Matsumoto K, et al. Development of an oral formulation of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, using n-lauryl-beta-D-maltopyranoside as an absorption enhancer. Biol Pharm Bull. 1999;22:611–615.
   PubMed Web of Science ®Google Scholar
• Swain SS, Sahoo BN, Mohanty S, et al. Prediction of the three-dimensional (3D) structure of somatostatin receptor type 1 of homo sapians by homology modelling. Res J Pharm, Biol Chem Sci. 2013;4:1510–1519.
   Google Scholar
• Maggio ET, Grasso P. Oral delivery of octreotide acetate in intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice. Regul Peptides. 2011 Apr 11;167:233–238. DOI:10.1016/j.regpep.2011.02.009.
   PubMed Web of Science ®Google Scholar
• Chen Z. inventor Peop. Rep. China. assignee. Octreotide acetate tablet with high compliance and bioavailability and preparation method thereof patent CN104667258A. 2015.
   Google Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocr Metab. 2012 Jul;97:2362–2369.
   PubMed Web of Science ®Google Scholar
• Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocr Metab. 2015 Apr;100:1699–1708.
   PubMed Web of Science ®Google Scholar
• Mansfeld FM, Toth I. Lipidated analogues of luteinizing hormone-releasing hormone (LHRH) reduce serum levels of follicle-stimulating hormone (FSH) after oral administration. Int J Pharmaceut. 2012 Dec 15;439:216–222. DOI:10.1016/j.ijpharm.2012.09.038.
   PubMed Web of Science ®Google Scholar
• Moradi SV, Varamini P, Toth I. Evaluation of the biological properties and the enzymatic stability of glycosylated luteinizing hormone-releasing hormone analogs. Aaps J. 2015 Sep;17:1135–1143. DOI:10.1208/s12248-015-9769-x.
   PubMed Web of Science ®Google Scholar
• Vrettos JS Formulating peptides/proteins for oral delivery: a clinical case study. AAPS National Meeting and Exposition; 2014; San Diego.
   Google Scholar
• Leung KC, Howe C, Gui LYY, et al. Physiological and pharmacological regulation of 20-kDa growth hormone. Am J Physiol-Endoc M. 2002;283:E836–E43.
   Google Scholar
• Iglesias P, Diez JJ. Clinical applications of recombinant human growth hormone in adults. Expert Opin Pharmacother. 1999 Nov;1:97–107. DOI:10.1517/14656566.1.1.97.
   PubMedGoogle Scholar
• Parmentier J, Hofhaus G, Thomas S, et al. Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. J Pharm Sci. 2014 Dec;103:3985–3993.
   PubMed Web of Science ®Google Scholar
• Amet N, Wang W, Shen W-C. Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release. 2010 Jan 25;141:177–182. DOI:10.1016/j.jconrel.2009.09.007.
   PubMed Web of Science ®Google Scholar
• Naether OG, Tandler-Schneider A, Bilger W. Individualized recombinant human follicle-stimulating hormone dosing using the CONSORT calculator in assisted reproductive technology: a large, multicenter, observational study of routine clinical practice. Drug Healthc Patient Saf. 2015;7:69–76. DOI:10.2147/DHPS.S77320.
   PubMedGoogle Scholar
• Low SC, Nunes SL, Bitonti AJ, et al. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod. 2005 Jul;20:1805–1813. DOI:10.1093/humrep/deh896.
   PubMed Web of Science ®Google Scholar
• Caldwell HK, Young WS III. Oxytocin and vasopressin: genetics and behavioral implications. Berlin: Springer; 2006. p. 573–607.
   Google Scholar
• Henriksen K, Bay-Jensen A-C, Christiansen C, et al. Oral salmon calcitonin - pharmacology in osteoporosis. Expert Opin Biol Th. 2010 Nov;10:1617–1629. DOI:10.1517/14712598.2010.526104.
   PubMed Web of Science ®Google Scholar
• Carl SM, Mehta N, Stern W. Oral delivery of peptides by PeptelligenceTM technology. Drug Dev Deliv. 2013;27:12–15.
   Google Scholar
• Binkley N, Bone H, Gilligan JP, et?al. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos Int. 2014;25(11):2649–2656.
   PubMed Web of Science ®Google Scholar
• Binkley N, Bolognese M, Sidorowicz-Bialynicka A, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27:1821–1829. DOI:10.1002/jbmr.1602.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Alexandersen P, et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthr Cartilage. 2015 Apr;23:532–543.
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004 Sep;19:1531–1538.
   PubMed Web of Science ®Google Scholar
• Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm. 2004;10:142–151.
   PubMedGoogle Scholar
• Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013 Dec;47:1675–1684. DOI:10.1177/1060028013509233.
   PubMed Web of Science ®Google Scholar
• Yan H, Guo ZY, Gong XW, et al. A peptide model of insulin folding intermediate with one disulfide. Protein Sci. 2003 Apr;12:768–775.
   PubMed Web of Science ®Google Scholar
• Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist study. Diabetes. 2010;59:2846–2853. DOI:10.2337/db10-0676.
   PubMed Web of Science ®Google Scholar
• Zijlstra E, Heinemann L, Plum-Morschel L. Oral insulin reloaded: a structured approach. J Diabetes Sci Technol. 2014 May;8:458–465. DOI:10.1177/1932296814529988.
   PubMedGoogle Scholar
• Delivering medical breakthroughs for Diabetes & Obesity. 2015. Available from: http://diasomepharmaceuticals.com/pipeline/
   Google Scholar
• Kidron M, Arbit E, Shushlav Y. Comparative assessment of the glucose-lowering effect of multiple oral insulin (ORMD-0801) formulation variants in pigs. Diabetes. 2014 Jun;63:A612–A.
   Google Scholar
• Eldor R, Kidron M, Arbit E. Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects. Diabetes Obes Metab. 2010 Mar;12:219–223. DOI:10.1111/j.1463-1326.2009.01153.x.
   PubMed Web of Science ®Google Scholar
• ORAMED pharmaceuticals Inc. ORAMED pharmaceuticals reports positive top-line data from U.S. Phase IIa trial with oral insulin in type 1 diabetes. ORMD-0801-Oral Insulin Capsule; 2014. Available from: http://www.oramed.com/pipeline/ormd-0801-type-2/
   Google Scholar
• ORAMED pharmaceuticals Inc . ORMD 0801 – oral insulin capsule for T2DM. ORMD-0801-Oral Insulin Capsule; 2014. Available from: http://www.oramed.com/pipeline/ormd-0801-type-2/
   Google Scholar
• Hoffman A, Qadri B. Eligen insulin - a system for the oral delivery of insulin for diabetes. Idrugs. 2008 Jun;11:433–441.
   PubMed Web of Science ®Google Scholar
• Hazra P, Adhikary L, Dave N, et al. Development of a process to manufacture PEGylated orally bioavailable insulin. Biotechnol Progr. 2010 Nov-Dec;26:1695–1704.
   PubMed Web of Science ®Google Scholar
• Stanton D Novo nordisk one step closer to long-acting oral insulin. In-Pharma Technologies. Montpellier: William Reed Business Media; 2013.
   Google Scholar
• Leone-Bay A, Sato M, Paton D, et al. Oral delivery of biologically active parathyroid hormone. Pharm Res-Dordr. 2001 Jul;18:964–970.
   PubMed Web of Science ®Google Scholar
• Emisphere Technology, Inc. Oral Parathyroid Hormone; 2015. Available from: http://www.emisphere.com/oral_recombinant_ph.html
   Google Scholar
• Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis. Bone. 2013 Mar;53:160–166.
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin J Am Soc Nephro. 2008 Jan;3:200–207. DOI:10.2215/CJN.03840907.
   PubMed Web of Science ®Google Scholar
• Bonomini M, Del Vecchio L, Sirolli V, et al. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2015;98:2422–2429.
   Google Scholar
• Garcia JM, Swerdloff R, Wang C, et al. Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocr Metab. 2013 Jun;98:2422–2429.
   PubMed Web of Science ®Google Scholar
• Zentaris A. Macrilen^TM: Evaluation of adult growth hormone deficiency (endocrinology); 2015. Available from: http://www.aezsinc.com/en/page.php?p=20&prod=43
   Google Scholar
• Mapelli C, Natarajan SI, Meyer J-P, et al. Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem. 2009 12 10;52:7788–7799. DOI:10.1021/jm900752a.
   PubMed Web of Science ®Google Scholar
• Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2013 Dec;28:262–274. DOI:10.3803/EnM.2013.28.4.262.
   PubMedGoogle Scholar
• Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther. 2012 Sep;135:247–278. DOI:10.1016/j.pharmthera.2012.05.009.
   PubMed Web of Science ®Google Scholar
• Zhang BJ, He DY, Fan Y, et al. Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate. Plos One. 2014 Jan 21;9(1):e86064.
   PubMed Web of Science ®Google Scholar
• Steinert RE, Poller B, Castelli MC, et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther. 2009 Dec;86:644–650. DOI:10.1038/clpt.2009.159.
   PubMed Web of Science ®Google Scholar
• Emisphere Technology, Inc. Emisphere Highlights Eligen Licensee Novo Nordisk’s Entry Into Phase 3a Development of Oral Semaglutide, a Once Daily Oral GLP-1; 2015. Available from: http://ir.emisphere.com/releasedetail.cfm?ReleaseID=928925
   Google Scholar
• Mehta NM. Oral delivery and recombinant production of peptide hormones. BioPharm International. 2004;17(7):44–46.
   Google Scholar
• Yin P, Bousquet-Moore D, Annangudi SP, et al. Probing the production of amidated peptides following genetic and dietary copper manipulations. Plos One. 2011 Dec 16;6:e28679. DOI:10.1371/journal.pone.0028679.
   Web of Science ®Google Scholar